Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685425 · ClinicalTrials.gov registry record · Phase 3
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT00685425: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT00685425 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 62 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00685425, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma
Interventions
- DRUG Levalbuterol HFA MDI
- DRUG Racemic Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
What the finished NCT00685425 record still lists
NCT00685425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Levalbuterol HFA MDI is the first listed.
NCT00685425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00685425 about?
NCT00685425 is a clinical study titled "Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol". The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma
What is the current status of trial NCT00685425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2002-10. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00685425?
The interventions under investigation include: Levalbuterol HFA MDI (DRUG), Racemic Albuterol (DRUG).
Who is sponsoring clinical trial NCT00685425?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00685425's enrollment target sits among peer trials
62 1802nd of 2000 higher than 198 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia